
The Galleri® multi-cancer early detection test — now available exclusively through Human Longevity. Detect cancer signals before symptoms appear, across cancers that have no recommended screening today.
HSA/FSA eligible · Rx required · For adults 50+ or those at elevated cancer risk
Human Longevity is proud to offer the Galleri® test by GRAIL — the first multi-cancer early detection blood test to achieve large-scale clinical validation with over 20,000 study participants, studied at leading cancer institutions worldwide.
Most cancers have no recommended screening tests today. Galleri® changes that — identifying a "cancer fingerprint" of methylation patterns in cell-free DNA shed by cancer cells into your bloodstream.
Request your Galleri test through Human Longevity. A physician order is placed and you schedule a convenient blood draw appointment.
A single 2-tube blood draw — no fasting, no prep. The test analyzes cell-free DNA shed by cancer cells into the bloodstream.
GRAIL's CLIA-certified clinical laboratory uses advanced methylation analysis to identify cancer signals and localize their tissue of origin.
Your HLI physician reviews your results with you. If a signal is detected, immediate next steps and diagnostic workup are coordinated.

The PATHFINDER and PATHFINDER 2 studies demonstrated that adding the Galleri test to standard recommended screenings approximately doubled the number of cancers detected — most in early, more treatable stages.
Studied at
Memorial Sloan Kettering · Dana-Farber · Cleveland Clinic · Mayo Clinic · Johns Hopkins · Intermountain Health · and 14 other leading cancer centers
A 2025 study published in Nature Communications analyzed real-world data from more than 100,000 multi-cancer early detection tests — the largest clinical experience reported to date. Across a median participant age of 58, the test detected invasive cancers spanning 32 distinct cancer types, many of which have no recommended screening available today.
Matrana M, Shukla V, Kingsbury D, et al. Real-world data and clinical experience from over 100,000 multi-cancer early detection tests. Nature Communications 16, 9625 (2025). doi.org/10.1038/s41467-025-64094-7 ↗
The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those age 50 or older. Galleri is not recommended for individuals who are pregnant, age 21 or younger, or undergoing active cancer treatment. Galleri does not detect all cancers and should not replace routine cancer screenings recommended by your healthcare provider. Results should be interpreted by a healthcare provider in the context of medical history. A test result of No Cancer Signal Detected does not rule out cancer. False positive and false negative results do occur. Rx only.
.png)
One blood draw. Over 50 cancers. Every order includes a full year of complimentary access to HLI's AI precision medicine app — turning your results into a longitudinal plan for your health.
A physician consultation is required. Human Longevity physicians will review eligibility and issue an order. Available to patients 50+ or those at elevated cancer risk.